325 related articles for article (PubMed ID: 32758252)
1. Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.
Li Q; Maier SH; Li P; Peterhansl J; Belka C; Mayerle J; Mahajan UM
Radiat Oncol; 2020 Aug; 15(1):189. PubMed ID: 32758252
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
3. Aptamers: potential applications to pancreatic cancer therapy.
Rialon KL; White RR
Anticancer Agents Med Chem; 2011 Jun; 11(5):434-41. PubMed ID: 21492073
[TBL] [Abstract][Full Text] [Related]
4. Aptamer applications for targeted cancer therapy.
Barbas AS; Mi J; Clary BM; White RR
Future Oncol; 2010 Jul; 6(7):1117-26. PubMed ID: 20624124
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.
Liu AD; Zhou J; Bi XY; Hou GQ; Li SS; Chen Q; Xu H; Cao X
Clin Transl Med; 2021 Mar; 11(3):e337. PubMed ID: 33783993
[TBL] [Abstract][Full Text] [Related]
6. Oligonucleotide aptamers for glioma targeting: an update.
Camorani S; Cerchia L
Cent Nerv Syst Agents Med Chem; 2015; 15(2):126-37. PubMed ID: 25924917
[TBL] [Abstract][Full Text] [Related]
7. Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma.
Champanhac C; Teng IT; Cansiz S; Zhang L; Wu X; Zhoa Z; Fu T; Tan W
Sci Rep; 2015 Nov; 5():16788. PubMed ID: 26603187
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
9. X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.
Wang H; Li X; Lai LA; Brentnall TA; Dawson DW; Kelly KA; Chen R; Pan S
Biochimie; 2021 Feb; 181():25-33. PubMed ID: 33242496
[TBL] [Abstract][Full Text] [Related]
10. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
11. The development and testing of aptamers for cancer.
Barbas AS; White RR
Curr Opin Investig Drugs; 2009 Jun; 10(6):572-8. PubMed ID: 19513946
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine.
Zhuo Z; Yu Y; Wang M; Li J; Zhang Z; Liu J; Wu X; Lu A; Zhang G; Zhang B
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036890
[TBL] [Abstract][Full Text] [Related]
13. Novel insights into the role of aptamers in the fight against cancer.
Maimaitiyiming Y; Hong F; Yang C; Naranmandura H
J Cancer Res Clin Oncol; 2019 Apr; 145(4):797-810. PubMed ID: 30830295
[TBL] [Abstract][Full Text] [Related]
14. A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma.
Clawson GA; Abraham T; Pan W; Tang X; Linton SS; McGovern CO; Loc WS; Smith JP; Butler PJ; Kester M; Adair JH; Matters GL
Nucleic Acid Ther; 2017 Feb; 27(1):23-35. PubMed ID: 27754762
[TBL] [Abstract][Full Text] [Related]
15. Aptamers in hematological malignancies and their potential therapeutic implications.
Ouyang W; Yu Z; Zhao X; Lu S; Wang Z
Crit Rev Oncol Hematol; 2016 Oct; 106():108-17. PubMed ID: 27637356
[TBL] [Abstract][Full Text] [Related]
16. Aptamers: molecular tools for medical diagnosis.
Ozalp VC; Kavruk M; Dilek O; Bayrac AT
Curr Top Med Chem; 2015; 15(12):1125-37. PubMed ID: 25866272
[TBL] [Abstract][Full Text] [Related]
17. Aptamer Selection for Detecting Molecular Target Using Cell-SELEX (Systematic Evolution of Ligands by Exponential Enrichment) Technology.
Stewart KD; Tan W; Park JY
Methods Mol Biol; 2019; 2054():223-241. PubMed ID: 31482459
[TBL] [Abstract][Full Text] [Related]
18. Advances of aptamers screened by Cell-SELEX in selection procedure, cancer diagnostics and therapeutics.
Zhong Y; Zhao J; Li J; Liao X; Chen F
Anal Biochem; 2020 Jun; 598():113620. PubMed ID: 32087127
[TBL] [Abstract][Full Text] [Related]
19. Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo.
Yoon S; Huang KW; Reebye V; Mintz P; Tien YW; Lai HS; Sætrom P; Reccia I; Swiderski P; Armstrong B; Jozwiak A; Spalding D; Jiao L; Habib N; Rossi JJ
Mol Ther; 2016 Jun; 24(6):1106-1116. PubMed ID: 26983359
[TBL] [Abstract][Full Text] [Related]
20. Selection and Application of Aptamers and Intramers.
Avci-Adali M
Adv Exp Med Biol; 2016; 917():241-58. PubMed ID: 27236559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
